Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Venarske

Allergy & Immunology Jackson, MS Medical Doctor

NPI 1003892357 CMS profile 317730

1513 Lakeland Dr., Suite 101, Jackson, MS 39216

Open in the dashboard

General payments

$155,691

846 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Venarske of Jackson, MS is reported in the CMS Open Payments database as having received $155,691 across 846 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38,313 194
2024 General $39,262 154
2023 General $27,635 160
2022 General $12,709 109
2021 General $12,899 108
2020 General $12,423 52
2019 General $12,451 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Venarske
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Daniel Venarske were reported at $38,313. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Daniel Venarske Allergy & Immunology median Middle half National median
2019 $12,451 $594 $163–$1,512 $163
2020 $12,423 $426 $106–$1,233 $114
2021 $12,899 $638 $157–$1,708 $132
2022 $12,709 $790 $205–$1,961 $149
2023 $27,635 $852 $220–$2,147 $160
2024 $39,262 $865 $203–$2,267 $164
2025 $38,313 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $75,932 183 payments
  2. AstraZeneca Pharmaceuticals LP $61,051 155 payments
  3. Pfizer Inc. $4,401 36 payments
  4. Genzyme Corporation $2,948 5 payments
  5. Regeneron Healthcare Solutions, Inc. $2,719 124 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $1,899 26 payments
  7. CSL Behring $1,669 62 payments
  8. Novartis Pharmaceuticals Corporation $1,300 68 payments
  9. Genentech USA, Inc. $577 30 payments
  10. Octapharma USA, Inc. $502 25 payments
  11. Other $2,692 132 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $132,585 57 payments
  2. Food and Beverage $18,567 759 payments
  3. Travel and Lodging $4,028 20 payments
  4. Education $313 8 payments
  5. Consulting Fee $198 2 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $52,514 77 payments
  2. AIRSUPRA $45,779 57 payments
  3. NUCALA Respiratory $22,569 37 payments
  4. TEZSPIRE $14,251 33 payments
  5. OCTAGAM IMMUNE GLOBULIN (HUMAN) $4,183 21 payments
  6. DUPIXENT Immunology $2,948 5 payments
  7. DUPIXENT Inflammation And Immunology $1,849 92 payments
  8. FASENRA $1,443 32 payments
  9. CINRYZE $1,347 3 payments
  10. BREZTRI $1,295 13 payments
  11. Other $10,209 504 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,419

Median for Allergy/ Immunology: 449

Drug cost

$161,789

Median for Allergy/ Immunology: $169,700

Branded share of claims

31.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 73 $51,899
Spiriva Respimat Tiotropium Bromide Brand 15 $17,172
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $16,989
Breo Ellipta Fluticasone/Vilanterol Brand 40 $14,747
Advair Hfa Fluticasone Propion/Salmeterol Brand 46 $14,609
Symbicort Budesonide/Formoterol Fumarate Brand 28 $9,502
Dulera Mometasone/Formoterol Brand 18 $6,219
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 33 $4,986
Azelastine Hcl Generic 146 $4,498
Breyna Budesonide/Formoterol Fumarate Brand 24 $4,204

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$1,018,422

Of which drugs: $898,855

Medicare patients

317

Average age 72

Services billed

49,118

217 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 30%
Diabetes 28%
Depression 22%
COPD 20%
Chronic kidney disease 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 11 11 $900

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$29,206 — —
TEZSPIRE
$5,996 — —
NUCALA
$1,749 — —
DUPIXENT
$595 — —
XOLAIR
$362 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

846 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record